DeepMed Research

Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer

Not Applicable

Conditions: Breast Neoplasms
Neoplasm Recurrence, Local

Interventions: Radiation: Accelerated Partial Breast Irradiation

First Posted Date: 2018-07-11

Last Posted Date: 2022-01-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 537

Registration Number: NCT03583580

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

Phase 2

Completed

Conditions: Head Neck Cancer
Vomiting
Nausea Post Chemotherapy

Interventions: Drug: Aprepitant

First Posted Date: 2018-06-28

Last Posted Date: 2020-07-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 44

Registration Number: NCT03572829

Locations: 🇨🇳
National Cancer Center/ Cancer Hospital, Chinese Academy of Medcal science and Peking Union Medical College, Beijing, China

New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma

Phase 2

Conditions: Hypopharyngeal Cancer

Interventions: Drug: Induction CT+ CRT group
Radiation: Concurrent CRT group

First Posted Date: 2018-06-15

Last Posted Date: 2021-01-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 96

Registration Number: NCT03558035

Locations: 🇨🇳
Cancer hospital, Chinese Academy of Medical Sciences, Beijing, China

Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer

Phase 1

Conditions: Colo-rectal Cancer

Interventions: Drug: Anlotinib Hydrochloride with Irinotecan

First Posted Date: 2018-06-04

Last Posted Date: 2018-08-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 42

Registration Number: NCT03545711

Locations: 🇨🇳
Jing Huang, Beijing, China

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: apatinib+oral etoposide

First Posted Date: 2018-05-24

Last Posted Date: 2020-12-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 32

Registration Number: NCT03535961

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer

Phase 1

Conditions: Gastric Cancer
Chemoradiation

Interventions: Radiation: Hypo-fractionated radiotherapy
Drug: S1

First Posted Date: 2018-02-09

Last Posted Date: 2018-02-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 18

Registration Number: NCT03427684

Locations: 🇨🇳
Cancer Hospital, Chinese academy of medical sciences, Beijing, Beijing, China

Factors Influencing Cancer Patients Participation in Clinical Trials in China.

Conditions: Cancer

First Posted Date: 2018-01-26

Last Posted Date: 2018-01-26

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT03412344

Locations: 🇨🇳
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China

Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Phase 2

Conditions: Experimental

Interventions: Drug: Chidamide

First Posted Date: 2018-01-25

Last Posted Date: 2018-01-25

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT03410004

Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

Phase 2

Conditions: Anal Cancer

Interventions: Radiation: Chemo-radiotherapy with IMRT technique
Drug: Capecitabine
Drug: Mitomycin C

First Posted Date: 2017-12-22

Last Posted Date: 2018-01-30

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 27

Registration Number: NCT03381352

Locations: 🇨🇳
Chinese academy of medical sciences, Beijing, Beijing, China

FSRT Combined With TMZ for Large BMs: a PSM Study

Completed

Conditions: Chemotherapy
Brain Metastases
Radiotherapy

Interventions: Radiation: fractionated stereotactic radiotherapy

First Posted Date: 2017-11-09

Last Posted Date: 2017-11-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 72

Registration Number: NCT03338075

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy